R
Richard B. Rothman
Researcher at National Institute on Drug Abuse
Publications - 350
Citations - 18487
Richard B. Rothman is an academic researcher from National Institute on Drug Abuse. The author has contributed to research in topics: Receptor & Agonist. The author has an hindex of 69, co-authored 350 publications receiving 17781 citations. Previous affiliations of Richard B. Rothman include Addiction Research Center & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.
Richard B. Rothman,Michael H. Baumann,Christina M. Dersch,Dana V. Romero,Kenner C. Rice,F. Ivy Carroll,John S. Partilla +6 more
TL;DR: In vitro methods determined the neurochemical mechanism of action of amphetamine, 3,4‐methylenedioxymethamphetamine (MDMA), (+)‐methamphetamine, ephedrine, phentermine, and aminorex, and demonstrated that the most potent effect of these stimulants is to release NE.
Journal ArticleDOI
A proposal for the classification of sigma binding sites.
Rémi Quirion,Wayne D. Bowen,Yossef Itzhak,Jean Louis Junien,JoséM M. Musacchio,Richard B. Rothman,Su Tsung-Ping,S. William Tam,Duncan P. Taylor +8 more
Journal ArticleDOI
Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist
Bryan L. Roth,Karen Baner,Richard B. Westkaemper,Daniel J. Siebert,Kenner C. Rice,Seanna Steinberg,Paul Ernsberger,Richard B. Rothman +7 more
TL;DR: Salvinorin A is the first naturally occurring nonnitrogenous opioid-receptor subtype-selective agonist for κ opioid receptors and may represent novel psychotherapeutic compounds for diseases manifested by perceptual distortions (e.g., schizophrenia, dementia, and bipolar disorders).
Journal ArticleDOI
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
Richard B. Rothman,Michael H. Baumann,Jason E. Savage,Laura Rauser,Ace McBride,Sandra J. Hufeisen,Bryan L. Roth +6 more
TL;DR: It is suggested that all clinically available medications with serotonergic activity and their active metabolites be screened for agonist activity at 5-HT2B receptors and that clinicians should consider suspending their use of medications with significant activity at5-HT1B receptors.
Journal ArticleDOI
Monoamine transporters and psychostimulant drugs.
TL;DR: The brain contains high abundance nonclassical binding sites for cocaine-like drugs that have micromolar affinity for cocaine and that none of the clinically available amphetamine-type appetite suppressants are equipotent substrates for dopamine transporter (DAT) and serotonin transporter (SERT) proteins.